ToPCaP

Publications

2016

• Tumor expression of adiponectin receptor 2 and lethal prostate cancer.
  

  Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis 2015;36(6):639-47.

• Risk of thromboembolic disease in men with prostate cancer on androgen deprivation therapy: A follow-up study in PCBaSe Sweden.
  

  O’Farrell, Sandstrom K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M. Risk of thromboembolic disease in men with prostate cancer on androgen deprivation therapy: A follow-up study in PCBaSe Sweden. BJUI (2015): In press.

• Prostate-specific antigen testing prevalence and prostate cancer risk factors in general practice: a cross-sectional study in inner London.
  

  Nderitu P, Van Hemelrijck M, Ashworth M, Mathur R, Hull S, Dudek A, Chowdhury S. Prostate-specific antigen testing prevalence and prostate cancer risk factors in general practice: a cross-sectional study in inner London. BMJ Open (2016): In press.

• Intracellular Location of BRCA2 Protein Expression and Prostate Cancer Progression in the Swedish Watchful Waiting Cohort.
  

  Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Intracellular Location of BRCA2 Protein Expression and Prostate Cancer Progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016 Jan 16. pii: bgw001. [Epub ahead of print]

• Interpretation of conventional survival analysis and competing risk analysis: An example of hypertension and prostate cancer.
  

  Haggstrom C, Stattin P, Stocks T, Garmo H, Holmberg L, Van Hemelrijck M. Interpretation of conventional survival analysis and competing risk analysis: An example of hypertension and prostate cancer. BJUI (2016): Published online March 31.

• Association of prostate cancer risk variants with TMPRSS2:ERG status: evidence for distinct molecular subtypes.
  

  Penney KL, Pettersson A, Shui IM, Graff RE, Kraft P, Lis RT, Sesso HD, Loda M, Mucci LA. Association of prostate cancer risk variants with TMPRSS2:ERG status: evidence for distinct molecular subtypes. Cancer Epidemiol Biomarkers Prev. 2016 Mar 3. pii: cebp.1078.2015. [Epub ahead of print]

• Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
  

  Crawley D, Garmo H, Rudman S, Stattin P, Haggstrom C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer (2016): In press.

• Association between baseline serum glucose, triglycerides and total cholesterol and prostate cancer risk categories.
  

  Arthur R, Møller H, Garmo H, Holmberg L, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M. Association between baseline serum glucose, triglycerides and total cholesterol and prostate cancer risk categories. Cancer Medicine (2016): Published online Feb 29.

2015

• Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men.
  

  Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, MucciLA. Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. Eur Urol. 2015 Feb;67(2):191-4. PMCID: PMC4318783.

• The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
  

  Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA; on behalf of the Transdisciplinary Prostate Cancer Partnership ToPCaP. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 June 15;75(9):897-906. PMCID: PMC4424159.

• Stress- Related Signaling Pathways in Lethal and Non-Lethal Prostate Cancer.
  

  Lu D, Sinnott JA, Valdimarsdottir UA, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA**, Fall K**. Stress-Related Signaling Pathways in Lethal and Non-Lethal Prostate Cancer. Clin Cancer Res. 2016 Feb 1;22(3):765-72. PMCID: PMC4738177 **Shared Last Authorship

• Sleep duration and disruption and prostate cancer risk: a 23-year prospective study.
  

  Markt SC, Flynn-Evans EE, Valdimarsdottir U, Sigurdardottir LG, Tamimi RM, Batista JL, Haneuse S, Lockley SW, Stampfer M, Wilson KM, Czeisler CA, Rider JR, Mucci LA. Sleep duration and disruption and prostate cancer risk: a 23-year prospective study. Cancer Epidemiol Biomarkers Prev. 2015 Dec 16. [EPub ahead of print]

• Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden.
  

  Ahrenfeldt LJ, Skytthe A, Möller S, Czene K, Adami HO, Mucci LA, Kaprio J, Petersen I, Christensen K, Lindahl-Jacobsen R. Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1622-8.

• Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: A meta-analysis.
  

  Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: A meta-analysis. Plos One (2015): Mar 20;10(3):e0117344. PMCID: PMC4368630

• Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark
  

  Moller H, Roswall N, Van Hemelrijck M, Benzon Larsen S, Cuzick J, Holmberg L, Overvad K, Tjonneland A. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark (2015). Int J Cancer: Apr 15;136(8):1940-7.

• Physical activity from early adulthood and risk of prostate cancer: a 24 year follow-up study among Icelandic men.
  

  Hrafnkelsdottir SM, Torfadottir JE, Aspelund T, Magnusson K, Tryggvadottir L Clinical Professor, Gudnason V, Mucci LA, Stampfer M, Valdimarsdottir UA. Physical activity from early adulthood and risk of prostate cancer: a 24 year follow-up study among Icelandic men. Cancer Prev Res (Phila). 2015 Oct;8(10):905-11.

• No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study.
  

  Liu H, Shui IM, Platz EA, Mucci LA, Giovannucci EL. No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1632-4.

• Molecular Differences in Transition Zone and Peripheral Zone Prostate Tumors.
  

  Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O. Molecular Differences in Transition Zone and Peripheral Zone Prostate Tumors. Carcinogenesis. 2015 Jun;36(6):632-8. PMC Journal –In Process.

• Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study.
  

  Bosco C, Wulaningsih W, Melvin J, Santaolalla A, De Piano M, Arthur R, Van Hemelrijck M. Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalsciences (2015): Jul 23;9:555.

• Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
  

  Martin NE, Gerke T, Sinnott JA, Stack EC, Andren O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct;13(10):1431-40. PMCID PMC4618038.

• Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.
  

  Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res. 2015 Oct 7. [Epub ahead of print]

• Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
  

  Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec;75(16):1926-33.

• Circadian clock genes and risk of fatal prostate cancer.
  

  Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, Harris T, Smith AV, Gudnason V, Lindstrom S, Kraft P, Mucci LA. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015; 26(1):25-33. PMCID: PMC4282953.

• CanWalk: an exploratory trial of the acceptability and feasibility of a walking intervention for people with recurrent or metastatic cancer. Pilot and feasibility studies (In Press)
  

  In press.

• Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.
  

  Binder M, Shui IM, Wilson KM, Penney KL; PRACTICAL/ELLIPSE Consortium, Mucci LA, Kibel AS. Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes Control. 2015 Dec;26(12):1751-9.

• ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).
  

  Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM, Giovannucci E, Haiman C, Henderson B, Hoover RN, Hunter DJ, Key TJ, Khaw KT, Canzian F, Larranga N, Le Marchand L, Ma J, Naccarati A, Siddiq A,Stampfer MJ, Stattin P, Stevens VL, Stram DO, Tjønneland A, Travis RC, Trichopoulos D, Ziegler RG, Lindstrom S, Kraft P, Mucci LA, Choueiri TK, Wilson KM. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 2015 Nov;75(15):1677-81.

• A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
  

  Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S,Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2015 Nov 27 [Print 2016 Feb]

• Serum lipids as markers of prostate cancer occurrence and prognosis.
  

  Arthur R, Rodriguez-Vida A, Zadra G, Moller H, Van Hemelrijck M. Serum lipids as markers of prostate cancer occurrence and prognosis. Clinical Lipidology (2015): 10(2):145-165.

• An investigation into the relationship between Statins and Cancer using population-based data.
  

  Melvin J, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Haggstrom C, Rudman S, Holmberg L, Van Hemelrijck M. An investigation into the relationship between Statins and Cancer using population-based data (2015). BJUI: Nov;116(5):681-3.

2014

• Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).
  

  Hernández B, Parnell A, Pennington SR. Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations). Proteomics 2014 Jul;14(13-14):1587-92.

• Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study.
  

  Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncology 2014: 2014 Sep 20;32(27):3033-8. PMCID: PMC4162499

• The High Prevalence of Undiagnosed Prostate Cancer at Autopsy: Implications for Epidemiology and Treatment of Prostate Cancer in the Prostate-Specific Antigen-Era”
  

  Jahn JL, Giovannucci EL, Stampfer MJ. The High Prevalence of Undiagnosed Prostate Cancer at Autopsy: Implications for Epidemiology and Treatment of Prostate Cancer in the Prostate-Specific Antigen-Era. International Journal of Cancer. 2015 Dec 15;137(12):2795-802. PMCID: PMC4485977

• The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer.
  

  Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E, Christensen K, Adami HO, Holm NV, Nuttall E, Hansen S, Hartman M, Czene K, Harris JR, Kaprio J, Mucci LA. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2303-10. PMCID: PMC4221420

• The biology and natural history of prostate cancer: a short introduction.
  

  Holmberg L, Van Hemelrijck M. The biology and natural history of prostate cancer: a short introduction. Recent Results Cancer Res. 2014;202:1-7

• SPINK1 Protein Expression and Prostate Cancer Progression
  

  Flavin R,Pettersson A, HendricksonWK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff PW, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15;20(18):4904-11. PMCID: PMC4167171

• Serum glucose and risk of cancer: a meta-analysis
  

  Crawley DJ, Holmberg L, Melvin JC, Loda M, Chowdhury S, Rudman SM, Van Hemelrijck M. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014 Dec 19;14(1):985. PMCID: PMC4320469

• Obesity and cancer: the role of vitamin D.
  

  Shanmugalingam T1, Crawley D, Bosco C, Melvin J, Rohrmann S, Chowdhury S, Holmberg L, Van Hemelrijck M. Obesity and cancer: the role of vitamin D. BMC Cancer. 2014 Sep 25;14:712. PMCID: PMC4182855

• Metformin Use and Prostate Cancer Risk.
  

  Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014 Dec;66(6):1012-20.

• Incidence of second malignancies for prostate cancer.
  

  Van Hemelrijck M, Feller A, Garmo H, Valeri F, Korol D, Dehler S, Rohrmann S. Incidence of second malignancies for prostate cancer. PLoS One. 2014 Jul 21;9(7). PMCID: PMC4105414

• Genetic variation across C-reactive protein and risk of prostate cancer.
  

  Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul;74(10):1034-42. PMCID: PMC4063346

• Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.
  

  Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW,Sweeney CJ. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb;74(3):225-34.

• Elevated IL-8, TNFα and MCP-1 in men with metastatic prostate cancer starting resistance and overall survival.
  

  Sharma J, Gray KP, Harshman LC, Evan E, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun;74(8):820-8.

• Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers
  

  Wallace TA, Downey RF, Seufert CJ, Schetter A, Dorsey TH, Johnson CA, Goldman R, Loffredo CA, Yan P, Sullivan FJ, Giles FJ, Wang-Johanning F, Ambs S, Glynn SA. Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis 2014 Sep;35(9):2074-83. PMCID: PMC4146419

• Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study.
  

  Alemozaffar M, Sanda M, Yecies D, Mucci LA, Stampfer MJ, Kenfield SA. Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study. Eur Urol. 2015 Mar;67(3):432-8. PMCID: PMC4128909

• 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer
  

  Mark A. Preston, MD, MPH; Kathryn M. Wilson, ScD; Sarah C. Markt, MPH, ScD; Rongbin Ge, PhD; Christopher Morash, MD; Meir J. Stampfer, MD, ScD; Massimo Loda, MD; Edward Giovannucci, MD, ScD; Lorelei A. Mucci, ScD; Aria F. Olumi, MD. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug;174(8):1301-7. PMCID: PMC4122627

• Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG positive prostate cancer.
  

  Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, Mucci LA. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2027-31. PMCID: PMC4184923

2013

• Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.
  

  Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013 Jun 18;346:f3406. PMCID: PMC3685512

• The fat side of prostate cancer.
  

  Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013 Oct;1831(10):1518-32. PMCID: PMC3766375

• Sleep disruption among older men and risk of prostate cancer.
  

  Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW. Sleep disruption among older men and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22(5):872-9. PMCID: PMC3652595

• Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses.
  

  Melvin J, Holmberg L, Rohrmann S, Loda M, Van Memelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J of Cancer Epidemiology 2013;2013:823849. PMCID: PMC3563167

• Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival.
  

  Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, Ma J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May;73(7):700-5. PMCID: PMC3640488

• Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study.
  

  Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn SP, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci EL. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. PMCID: PMC3818474

• Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
  

  Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2013;22:2354-63. PMCID: PMC3893763

• Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death.
  

  Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. Cancer Discovery 2013 Oct;3(10):1130-41. PMCID: PMC3797255

• Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer.
  

  Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, Dupre N, Giovannucci E and Mucci LA. Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. Eur Urol 2014 Apr;65(4):683-9. PMCID: PMC3664134

• Mortality following hip fracture in men with prostate cancer.
  

  Van Hemelrijck M, Garmo H, Michaelsson K, Thorstenson A, Akre O, Stattin P, Holmberg L, Adolfsson J. Mortality following hip fracture in men with prostate cancer. Plos One 2013 Sep 27;8(9):e74492. PMCID: PMC3785484

• Gleason Grade Progression Is Uncommon
  

  Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15;73(16):5163-5168. PMCID: PMC3775342

• ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
  

  Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH and Li Z. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013;27(6):683-98. PMCID: PMC3613614

• ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
  

  Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP and Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013;123(3):1109-22. PMCID: PMC3582143

• Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.
  

  Morrissey B, O'Shea C, Armstrong J, Rooney C, Staunton L, Sheehan M, Shannon AM, Pennington SR. Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy. Proteomics Clin Appl. 2013 Jun;7(5-6):316-26.

• Consumption of Fish Products across the Lifespan and Prostate Cancer Risk.
  

  Torfadottir JE, Valdimarsdottir UA, Mucci LA, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Gudnason V, Adami HO, Stampfer M, Steingrimsdottir L. Consumption of Fish Products across the Lifespan and Prostate Cancer Risk. PLoS One. 2013 Apr 17;8(4):e59799. PMCID: PMC3629172

• Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk.
  

  Shui IM, Mucci LA, Wilson KM, Kraft P, Penney KL, Stampfer MJ and Giovannucci E. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22(1):118-26. PMCID: PMC3538912

• Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.
  

  Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 1;73(9):2718-36. PMCID: PMC3644021

• A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer.
  

  Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ and Mucci LA. A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clin Cancer Res 2013;19(6):1612-9. PMCID: PMC3602407

• A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
  

  Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S,Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul;45(7):747-55. PMCID: PMC3787876

2012

• Vitamin D-related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Case-Control Study.
  

  Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, DuPre N, Platz EA, Stampfer MJ, Giovannucci E. Vitamin D-related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Case-Control Study. JNCI 2012 May 2;104(9):690-9. PMCID: PMC3341310

• Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry.
  

  Fiore C, Bailey D, Conlon N, Wu X, Martin N, Fiorentino M, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R. Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. J Clin Pathol. 2012 Jun;65(6):496-502. PMCID: PMC3437674

• The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
  

  Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M and Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21(9):1497-509. PMCID: PMC3671609

• The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study.
  

  Moller E, Galeone C, Adami HO, Adolfsson J, Andersson TM, Bellocco R, Gronberg H, Mucci LA and Balter K. The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study. Public Health Nutr 2012;15(10):1897-908.

• Temporal trends in cause of death among Swedish and US men with prostate cancer.
  

  Epstein MM, Edgren G, Rider JR, Mucci LA and Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104(17):1335-42. PMCID: PMC3529593

• Rye bread consumption in early life and reduced risk of advanced prostate cancer.
  

  Torfadottir JE, Valdimarsdottir UA, Mucci L, Stampfer M, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Adami HO, Gudnason V and Steingrimsdottir L. Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes Control 2012;23(6):941-50. PMCID: PMC3568695

• Milk intake in early life and risk of advanced prostate cancer.
  

  Torfadottir JE, Steingrimsdottir L, Mucci L, Aspelund T, Kasperzyk JL, Olafsson O, Fall K, Tryggvadottir L, Harris TB, Launer L, Jonsson E, Tulinius H, Stampfer M, Adami HO, Gudnason V and Valdimarsdottir UA. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol 2012;175(2):144-53. PMCID: PMC3249408

• Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden.
  

  Etzioni R, Mucci L, Chen S, Johansson JE, Fall K and Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012;18(24):6742-7. PMCID: PMC3711175

• Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
  

  Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM and Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 2012;33(2):404-12. PMCID: PMC3271270

• Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden.
  

  Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, Hakansson N, Fall K, Andersson SO and Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol 2012;176(3):240-52. PMCID: PMC3491963

• Alpha-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians’ Health Study and Health Professionals Follow-up Study.
  

  Barry M, Dhillon PK, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, Mucci LA, Rubin MA. Alpha-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians’ Health Study and Health Professionals Follow-up Study. Prostate 2012: 2(3):301-306. PMCID: PMC3267640

2011

• Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.
  

  Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. JCO 2011; 29(17): 2378-2385. PMCID: PMC3107752

• Smad 4-depedent barrier contrains prostate cancer growth and metastatic progression.
  

  Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Labrot ES, Zheng H, Stegh AH, Scott KL, Signoretti S, El-Bardessy NM, Wang YA, Hill D, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA. SMAD 4-depedent barrier contrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-73. PMCID: PMC3753179

• Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose.
  

  Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, Lambe M. Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose. Cancer (2011): 17(10):2086-95.

• Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.
  

  Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducrée J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O'Leary J. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6(10):e26125. PMCID: PMC3192146

• Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.
  

  Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control (2011): 22(7):1011-9.

• Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.
  

  Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K and Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(10):2280-7. PMCID: PMC3671592

• IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.
  

  Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012 Feb;107(2):196-204.

• Dietary zinc and prostate cancer survival in a Swedish cohort.
  

  Epstein MM, Kasperzyk JL, Andren O, Giovannucci EL, Wolk A, Hakansson N, Andersson SO, Johansson JE, Fall K and Mucci LA. Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr 2011;93(3):586-93. PMCID: PMC3041600

• Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.
  

  Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ and Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2618-27. PMCID: PMC3700351

• An mRNA expression signature of Gleason grade predicts lethal prostate cancer.
  

  Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Sesso H, Setlur S, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andren O, Stampfer MJ, Mucci LA. An mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011 Jun 10;29(17):2391-6. PMCID: PMC3107753

2010

• Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation.
  

  Van Hemelrijck M, Jungner I, Walldius G, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L, Hammar N. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer (2010): 129(6):1485-92.

• Molecular Sampling of Prostate Cancer: a dilemma for predicting disease progression.
  

  Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O. Molecular Sampling of Prostate Cancer: a dilemma for predicting disease progression. BMC Genomics 2010; 3:8. PMCID: PMC2855514

• Immunohistochemical expression of BRCA1 and lethal prostate cancer.
  

  Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Loda M, Mucci L. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010; ;70(8):3136-9. PMCID: PMC3049266

• Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer.
  

  Fang F, Valdimarsdottir U, Mucci L, Sparen P, Ye W and Fall K. Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. Cancer Epidemiol 2010;34(5):644-7.

• Homogeneous prostate cancer mortality in the Nordic countries over four decades.
  

  Meyer MS, Mucci LA, Andersson SO, Andren O, Johansson JE, Tretli S and Adami HO. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol 2010;58(3):427-32. PMCID: PMC2936655

• Genetic variation in RNASEL associated with prostate cancer risk and progression.
  

  Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep;31(9):1597-603. PMCID: PMC2930803

• Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk and Survival.
  

  Nguyen PL, Ma J, Chavarro J, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher F, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk and Survival. J Clin Oncology 2010 Sep 1;28(25):3958-64. PMCID: PMC2940394

• B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
  

  Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. PMCID: PMC2890809

• Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.
  

  Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLOS Genetics 2010 Nov 11;6(11):e1001204. PMCID: PMC2978684

2009

• Systems-level modeling of cancer-fibroblast interaction.
  

  Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S. Systems-level modeling of cancer-fibroblast interaction. PLoS One. 2009 Sep 3;4(9):e6888. PMCID: PMC2731225

• Season of diagnosis and prognosis in breast and prostate cancer.
  

  Holmberg L, Adolfsson J, Mucci L, Garmo H, Adami HO, Moller H, Johansson JE and Stampfer M. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 2009;20(5):663-70.

• Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.
  

  Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S and Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 2008;88(12):1340-8. PMCID: PMC3223737

• One-carbon metabolism-related nutrients and prostate cancer survival.
  

  Kasperzyk, JL, Fall K, Mucci LA, Hakansson N, Wolk A, Johansson JE, Andersson SO, Andren O. One-Carbon metabolism-related nutrients and prostate cancer survival. Am J Clin. Nutr. 2009 Sep;90(3):561-9. PMCID: PMC2728642

• No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.
  

  Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, MA J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate 2008 Sep 15;68(13):1416-20. PMCID: PMC2958090

• Incidence and mortality of incidental prostate cancer: a Swedish register-based study.
  

  Andren O, Garmo H, Mucci L, Andersson SO, Johansson JE and Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009;100(1):170-3. PMCID: PMC2634678

• Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.
  

  Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdottir U and Fall K. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010;102(5):307-14.

• Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study.
  

  Fall K, Fang F, Mucci LA, Ye W, Andren O, Johansson JE, Andersson SO, Sparen P, Klein G, Stampfer M, Adami HO and Valdimarsdottir U. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS 2009 Dec;6(12):e1000197. PMCID: PMC2784954

• Gleason score and lethal prostate cancer: does 3+4 = 4+3?
  

  Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein A, Kurth T, Loda M, Giovannucci E, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3+4 = 4+3? J Clin Oncol 2009 Jul 20;27(21):3459-64. PMCID: PMC2717753

• Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer.
  

  Migita T, Ruiz S, Fornari A, Inazuka F, Fiorentino M, Zadra G, Grisanzio C, Palescandolo E, Priolo C, Shin E, Fiore C, Xie W, Kung A, Mucci L, Ma J, Signoretti S, Stampfer M , Hahn W, Finn S, Loda M. Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer J Natl Cancer Inst 2009 Apr 1;101(7):519-32. PMCID: PMC2664091

• Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression.
  

  Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. Cancer Res. 2009 Jul 1;69(13):5568-74. PMCID: PMC2884104

• Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
  

  Setlur S, Mertz K, Hoshida Y, Demichelis D, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Vernhorst E, Johansson JE, Brown M, Golub TR, Rubin MA. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100(11):815-25. PMCID: PMC3073404

• Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.
  

  Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009 May;119(5):1093-108. PMCID: PMC2673846

• Aberrant cytoplasmic expression of p63 and prostate cancer mortality.
  

  Dhillon P, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari M, Ma J, Fleet J, Kurth T, Loda M, Rubin MA, Mucci LA. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009 Feb;18(2):595-600. PMCID: PMC2692093

• A prospective study of prostate tumor angiogenesis and cancer-specific mortality in the Health Professionals Follow-up Study.
  

  Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield S, Shen R, Stampfer MJ, Clinton SK. A prospective study of prostate tumor angiogenesis and cancer-specific mortality in the Health Professionals Follow-up Study. J Clin Oncology 2009; Nov 20;27(33):5627-33. PMCID: PMC2792955